Charles River Laboratories Financial Model
Healthcare Services Company Financials Example (Free Excel Download)
Charles River Laboratories is a leading early-stage contract research organisation (CRO) that provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts.
professionals from Deloitte
Used by professionals from
About this model
To forecast Charles River Laboratories' (CRL) consolidated cash flows and earnings to determine equity valuation, specifically assessing the impact of biopharmaceutical funding environments, non-human primate (NHP) supply dynamics, and recent strategic divestitures on future growth and margin recovery.
- Charles River Laboratories is a leading early-stage contract research organisation (CRO) that provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts.
- Business segments:
- Discovery and Safety Assessment (DSA): ~60% of revenue
- Research Models and Services (RMS): ~21% of revenue
- Manufacturing Solutions (Manufacturing): ~19% of revenue
- Key geographies: North America (~53% of revenue), Europe (~30%), and Asia-Pacific (with China being a critical market for NHP supply).
- Business model type: Service-based but infrastructure-heavy. The company requires significant physical footprint (vivaria, specialised laboratories) and biological assets (research models) to deliver its services.
- Competitive position: The undisputed market leader in in-vivo biology, safety assessment, and research models. Key competitors include Labcorp, ICON, Eurofins, and WuXi AppTec.
- Recent major events: In February 2026, CRL announced definitive agreements to divest its European Discovery Services assets, as well as its CDMO and Cell Solutions businesses (representing ~7% of 2025 revenue). The company also recorded massive non-cash goodwill and intangible asset impairments in Q4 2024 and Q4 2025 due to challenging market conditions in the CDMO and Discovery spaces.
The downloadable Charles River Laboratories financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsCharles River Laboratories financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Amortization of intangible assets | $124.9M | $146.6M | $137.4M | $138.5M | $179.1M |
| Operating income | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M |
| Net income | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Charles River Laboratories
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Discovery and Safety Assessment (DSA)
- Segment name: Discovery and Safety Assessment (DSA)
- Revenue driver formula: `Number of Studies x Average Revenue per Study` (driven by net bookings and backlog conversion).
- Historical growth rate: Historically 7-10% CAGR, but recently contracted (-6.3% in 2024, -2.0% in 2025).
- Key growth levers and headwinds: Driven by biotech funding levels and IND (Investigational New Drug) application volumes. Headwinds include biopharma budget constraints and pricing pressure.
- Pricing dynamics: Contractual, milestone-based. NHP costs are often passed through to clients, which can inflate revenue figures without corresponding margin expansion.
- Revenue recognition notes: Recognised over time using the percentage-of-completion method based on costs incurred relative to total estimated costs.
- Seasonality: Q4 is typically the strongest quarter due to year-end budget flush from biopharma clients.
Research Models and Services (RMS)
- Segment name: Research Models and Services (RMS)
- Revenue driver formula: `Volume of Models Sold x Price per Model` + `Service Contract Revenue`.
- Historical growth rate: 2-5% CAGR (grew 4.7% in 2024, 2.0% in 2025).
- Key growth levers and headwinds: Driven by early-stage basic research volume. A major headwind is the global supply constraint of non-human primates (NHPs), particularly from China and Cambodia.
- Pricing dynamics: Spot pricing for small models; contractual pricing for large models (NHPs) and insourcing solutions.
- Revenue recognition notes: Recognised at a point in time upon shipment of the research model.
- Seasonality: Q1 and Q4 are generally stronger; Q3 is typically weaker due to summer holidays in academic and European institutions.
Manufacturing Solutions
- Segment name: Manufacturing Solutions
- Revenue driver formula: `Testing Volume x Price per Test` (Microbial Solutions) + `Batches Manufactured x Price per Batch` (CDMO).
- Historical growth rate: Historically 8-12% CAGR, but heavily impacted by recent CDMO weakness.
- Key growth levers and headwinds: Driven by the number of biologic drugs in commercial production and clinical trials. The CDMO business has been a major drag, leading to its planned divestiture in 2026.
- Pricing dynamics: Highly regulated, sticky pricing for quality control testing (Microbial Solutions).
- Revenue recognition notes: Testing services recognised upon delivery of results; CDMO recognised over time.
- Seasonality: Relatively evenly distributed throughout the year.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Direct lab labour (scientists, technicians), animal costs (breeding, housing, feed, and third-party NHP procurement), facility overhead (utilities for vivaria), and laboratory consumables.
- Gross margin range: 35% - 39% historically, compressing recently towards the lower end due to unabsorbed capacity.
- Key input costs and commodity exposures: Cost of biological assets (NHPs have seen extreme price volatility), specialised animal feed, and highly skilled scientific labour.
- How COGS scales with revenue: Step-function. Animal care and facility costs are relatively fixed in the short term. Margin expansion relies heavily on facility utilisation rates.
Operating Expenses
- R&D: Not reported as a separate major line item; most scientific work is client-sponsored and sits in COGS.
- SG&A: Typically 15-18% of revenue. Driven by corporate headcount, IT infrastructure, and sales teams.
- Depreciation & Amortisation: Significant. D&A runs at ~6-8% of revenue, heavily weighted towards amortisation of acquisition-related intangibles.
- Stock-Based Compensation: ~1.5-2.0% of revenue.
- Restructuring / one-time charges: Highly frequent. The company has executed multiple site consolidations and recorded massive goodwill/intangible impairments (e.g., $376 million in Q4 2025 alone).
Margin Profile
- Gross margin: 35-39%
- EBITDA margin (Adjusted): 23-26%
- Operating margin (GAAP): Highly volatile due to impairments (dropped to negative in Q4 2024/2025; full year GAAP OM was 5.6% in 2024).
- Operating margin (Non-GAAP): 19.5% - 21.0% consolidated.
- Segment-level margins (Non-GAAP 2025): RMS ~24.8%, DSA ~24.2%, Manufacturing ~27-28%.
Balance Sheet Structure
- Total assets: ~$7.5 - $8.0 billion.
- Key asset categories: Goodwill and Intangibles make up the vast majority of assets due to a history of serial acquisitions. Property, Plant, and Equipment (PP&E) is also significant (laboratories and vivaria).
- Goodwill & intangibles as % of total assets: ~60-65% (though decreasing due to recent massive impairments).
- Working capital profile:
- Days Sales Outstanding (DSO): 45-55 days.
- Days Inventory Outstanding (DIO): 50-65 days (inventory includes live biological assets and NHPs).
- Days Payable Outstanding (DPO): 35-45 days.
- Net working capital as % of revenue: ~5-8%.
- Is working capital positive or negative? Positive. The company requires working capital to fund NHP inventory and lab supplies.
- PP&E: Consists of specialised laboratory equipment, animal housing facilities, and leasehold improvements. Useful lives: Buildings up to 40 years, equipment 3-10 years.
- Right-of-use assets / operating leases: Material (~$300-$400 million), representing leased laboratory and office space.
Capital Expenditure & Investment
- Capex as % of revenue: 5.0% - 7.0%.
- Maintenance capex vs. growth capex: Approximately 40% maintenance / 60% growth (capacity expansion for animal housing and safety assessment labs).
- Major capex programmes underway or planned: Expanding NHP quarantine capacity and upgrading legacy IT systems.
- Capitalised software / development costs: Minimal compared to physical infrastructure.
- M&A pattern: Historically a serial bolt-on and transformational acquirer (e.g., Cognate, Vigene, Noveprim). Currently pausing M&A to focus on divestitures and debt paydown.
- Typical acquisition multiple paid: Historically 15x-20x EBITDA for gene therapy and CDMO assets (which subsequently faced impairments).
Debt & Capital Structure
- Total debt: ~$2.6 - $2.9 billion.
- Debt/EBITDA ratio: Target is <3.0x. Currently hovering around 2.5x - 2.8x on an adjusted basis.
- Credit rating: Ba1 (Moody's) / BBB- (S&P) - crossover/low investment grade.
- Key debt instruments: Senior unsecured notes, a large revolving credit facility, and term loans.
- Maturity profile: Staggered, with significant senior notes maturing in 2028 and 2029.
- Interest rate profile: Mix of fixed bonds and floating rate term loans. Weighted average cost of debt is ~4.5 - 5.5%.
- Covenants: Maximum gross leverage ratio and minimum interest coverage ratio on the credit facility.
- Share repurchase programme: Highly active. Board approved a $1.0 billion authorisation in mid-2024.
- Dividend policy: The company does not pay a dividend, preferring share buybacks and debt reduction.
Cash Flow Characteristics
- Operating cash flow conversion: Strong. OCF / Non-GAAP Net Income is typically 1.1x - 1.3x.
- Free cash flow margin: 10% - 14% of revenue.
- Major non-cash items that bridge net income to OCF: Massive goodwill and intangible impairments, depreciation, amortisation of intangibles, and stock-based compensation.
- Working capital cash flow impact: Periodic drag when building NHP inventory, but generally stable.
- Capex intensity: Moderate (5-7%), requiring consistent reinvestment to maintain GLP (Good Laboratory Practice) compliance.
- Cash tax rate vs. GAAP effective tax rate: Cash tax rate is typically lower than the statutory rate due to R&D tax credits and excess tax benefits from stock-based compensation. Effective tax rate is highly volatile on a GAAP basis due to non-deductible goodwill impairments.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic factors, segment growth, margins, working capital days, and capital structure.
- Scenario Manager: Toggles for Base, Bull, and Bear cases (specifically flexing NHP supply constraints and biopharma funding recovery).
- Revenue & Segment Build: Detailed build for RMS, DSA, and Manufacturing. Includes volume/price drivers and explicit deductions for the 2026 divestitures (CDMO/Cell Solutions/European Discovery).
- Income Statement: Consolidated view mirroring the 10-K, from Revenue down to Net Income Available to Common Shareholders. Includes explicit lines for Restructuring and Impairment charges.
- Non-GAAP Reconciliation: Critical sheet bridging GAAP Operating Income to Non-GAAP Operating Income (adding back amortisation, impairments, restructuring).
- Balance Sheet: Standard assets, liabilities, and equity. Explicit lines for Goodwill, Intangible Assets, and Biological Inventory.
- Cash Flow Statement: Indirect method starting from GAAP Net Income.
- Working Capital Schedule: Forecasts Accounts Receivable, Inventory (including biological assets), and Accounts Payable based on days assumptions.
- Depreciation, Amortisation & Capex: Waterfall for PP&E and Intangibles.
- Debt Schedule: Tranches of Senior Notes, Term Loans, and Revolver. Calculates interest expense and tracks leverage covenants.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, and terminal value.
Key Financial Relationships
- `RMS Revenue = Prior Year RMS Revenue x (1 + RMS Organic Growth Rate) + FX Impact`
- `DSA Revenue = Prior Year DSA Revenue x (1 + DSA Organic Growth Rate) + FX Impact`
- `Manufacturing Revenue = Prior Year Mfg Revenue x (1 + Mfg Organic Growth Rate) - Divested CDMO/Cell Solutions Revenue`
- `Consolidated Revenue = RMS Revenue + DSA Revenue + Manufacturing Revenue`
- `Segment Operating Income = Segment Revenue x Segment Non-GAAP Operating Margin`
- `Unallocated Corporate Costs = Consolidated Revenue x Corporate Cost % (historically ~5-6%)`
- `Non-GAAP Operating Income = Sum of Segment Operating Incomes - Unallocated Corporate Costs`
- `GAAP Operating Income = Non-GAAP Operating Income - Amortisation of Intangibles - Restructuring Costs - Impairment Charges`
- `Inventory Balance = (Consolidated COGS / 365) x Days Inventory Outstanding`
- `Interest Expense = (Beginning Total Debt + Ending Total Debt) / 2 x Weighted Average Interest Rate`
- `Free Cash Flow = Operating Cash Flow - Capital Expenditures`
- `Adjusted EBITDA = Non-GAAP Operating Income + Depreciation + Stock-Based Compensation`
Cross-Sheet Dependencies
- Revenue & Segment Build feeds the top line of the Income Statement.
- Income Statement (GAAP Net Income) is the starting point for the Cash Flow Statement.
- Non-GAAP Reconciliation pulls from the Income Statement and feeds the DCF Valuation (to ensure cash taxes and unlevered free cash flows are calculated excluding non-cash impairments).
- Working Capital Schedule calculates changes in operating assets/liabilities, which feed the Cash Flow Statement.
- Debt Schedule calculates interest expense, which feeds the Income Statement, creating a potential circularity if the Revolver is used to fund cash shortfalls. A circuit breaker (iteration toggle) must be included.
- Cash Flow Statement ending cash balance feeds the Balance Sheet cash line.
Sign Convention
- Income Statement: Revenue is positive. Expenses (COGS, SG&A, Interest, Taxes) are negative.
- Balance Sheet: Assets are positive. Liabilities and Equity are positive.
- Cash Flow Statement: Cash inflows (e.g., Net Income, Depreciation add-back, increase in Payables) are positive. Cash outflows (e.g., Capex, increase in Receivables, debt repayment) are negative.
- Formulas: Gross Margin = `(Revenue + COGS) / Revenue` (assuming COGS is negative).
Things Most Likely to Go Wrong
- Ignoring the 2026 Divestitures: The model must explicitly remove ~$200 million in revenue and associated costs starting in 2026 for the CDMO, Cell Solutions, and European Discovery divestitures. Failing to do so will overstate future revenue.
- GAAP vs. Non-GAAP Confusion: CRL's GAAP earnings are currently decimated by hundreds of millions in goodwill impairments. Valuation and margin analysis *must* be done on a Non-GAAP basis, or the business will appear structurally unprofitable.
- NHP Pass-Through Revenue: High NHP prices inflate DSA revenue but carry zero margin. If NHP prices fall, revenue growth will look artificially negative while margins mathematically expand.
- Unallocated Corporate Costs: Segment operating margins are reported *before* corporate overhead. Summing segment operating income does not equal consolidated operating income.
- Biological Asset Inventory: Inventory behaves differently than a standard manufacturer; live animals require ongoing feed and care costs even if not sold, impacting COGS regardless of revenue volume.
- Amortisation Burden: Because of serial acquisitions, amortisation is a massive non-cash expense. Excluding it from adjusted metrics is standard practice for CRL.
- Foreign Exchange Sensitivity: With ~47% of revenue outside North America, constant-currency views are essential. The model should have an explicit FX impact line.
- Circularity in Debt Paydown: CRL uses excess cash to aggressively buy back stock and pay down debt. The model needs a clear cash sweep logic to prevent circular reference errors.
Validation Checks
- "Consolidated Non-GAAP Operating Margin should be in the 19.0% - 21.0% range; flag if outside this band."
- "Unallocated Corporate Costs should equal approximately 5.0% - 6.0% of total revenue."
- "Capex as % of revenue must remain between 5.0% and 7.0% to maintain GLP facility compliance."
- "Debt/Adjusted EBITDA should remain below 3.0x per credit facility covenants."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period (Check = 0)."
- "Free Cash Flow conversion (FCF / Non-GAAP Net Income) should be between 0.8x and 1.1x."
- "Effective tax rate (Non-GAAP) should be between 21.0% and 23.5%."
- "Total Segment Revenue must exactly equal Consolidated Revenue before FX adjustments."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| RMS Organic Revenue Growth | 1.5 | % | Reflects stable but low-growth basic research demand and NHP supply constraints (2025 actual was 1.2%). |
| DSA Organic Revenue Growth | -1.0 | % | Reflects stabilizing but still constrained biopharma funding environment (2025 actual was -2.6%). |
| Mfg Organic Revenue Growth | 2.0 | % | Reflects steady Microbial Solutions growth, excluding the divested CDMO business. |
| Divestiture Revenue Impact (2026) | -200.0 | $M | Management guidance for the sale of CDMO, Cell Solutions, and EU Discovery assets. |
| RMS Non-GAAP Operating Margin | 24.5 | % | In line with 2025 actual of 24.8%. |
| DSA Non-GAAP Operating Margin | 24.0 | % | In line with 2025 actual of 24.2%. |
| Mfg Non-GAAP Operating Margin | 28.0 | % | Improvement expected post-divestiture of lower-margin CDMO business. |
| Unallocated Corporate Costs | 5.5 | % of Rev | Historical average required to bridge segment to consolidated margins. |
| Days Sales Outstanding (DSO) | 50 | Days | Based on historical accounts receivable turnover. |
| Days Inventory Outstanding (DIO) | 60 | Days | Reflects holding periods for biological assets and lab supplies. |
| Days Payable Outstanding (DPO) | 40 | Days | Based on historical accounts payable trends. |
| Capex as % of Revenue | 6.0 | % | Midpoint of historical 5-7% range for facility maintenance and expansion. |
| Non-GAAP Effective Tax Rate | 22.5 | % | Management guidance for normalized tax rate. |
| Weighted Average Interest Rate | 5.0 | % | Based on current mix of fixed notes and floating rate debt. |
| Share Repurchases | 250.0 | $M/Year | Assumes continued execution against the $1.0B authorisation. |
| WACC | 8.5 | % | Standard discount rate for a CRO with CRL's beta and leverage profile. |
| Terminal Growth Rate | 2.5 | % | Long-term growth rate aligning with global R&D spending growth. |
Data Sources & Benchmarks
- Filings: SEC EDGAR (10-K, 10-Q, 8-K) and Charles River Laboratories Investor Relations website (ir.criver.com) for earnings presentations and non-GAAP reconciliations.
- Key Peers for Benchmarking: Labcorp (LH), ICON plc (ICLR), IQVIA (IQV), Eurofins Scientific (ERF.PA).
- Industry Data Sources: IQVIA Institute for Human Data Science (for clinical trial starts and R&D funding trends), PitchBook (for biotech venture capital funding levels).
- Consensus Estimates: FactSet or Bloomberg for forward-looking revenue and EPS consensus.
- Proprietary Data: Import/Export customs data (for tracking NHP shipments from Asia to North America).
Sources
- Charles River Laboratories Q4 2025 Earnings Release and Presentation (February 18, 2026)
- Charles River Laboratories Q4 2024 Earnings Release and Presentation (February 19, 2025)
- Charles River Laboratories 2024 Annual Report on Form 10-K
- SEC EDGAR Database (https://www.sec.gov/edgar/searchedgar/companysearch)
- Charles River Investor Relations (https://ir.criver.com)
Do more with the Charles River Laboratories model
Frequently asked
What does Charles River Laboratories do?+
Charles River Laboratories (CRL) is a leading early-stage contract research organization (CRO) that provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. They help accelerate research and drug development efforts through their Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions segments.
What are the main revenue drivers for Charles River Laboratories?+
Charles River Laboratories' revenue is primarily driven by its Discovery and Safety Assessment services, which account for approximately 60% of its revenue. Other significant drivers include Research Models and Services (21%) and Manufacturing Solutions (19%), all supporting the drug development lifecycle.
What is Charles River Laboratories' typical capital expenditure as a percentage of revenue?+
Charles River Laboratories typically allocates 5.0% to 7.0% of its revenue to capital expenditure. This capex is split approximately 40% for maintenance and 60% for growth, funding capacity expansion for animal housing and safety assessment labs.
How does Charles River Laboratories' working capital profile impact its financial model?+
Charles River Laboratories has a positive net working capital profile, typically ranging from 5-8% of revenue, which is essential for funding live biological assets like NHP inventory and lab supplies. This positive working capital requirement is an important input for cash flow projections in a financial model.
Can I download a financial model for Charles River Laboratories (CRL)?+
Yes, a downloadable Excel financial model is available for Charles River Laboratories (CRL). This model forecasts consolidated cash flows and earnings from FY2026 to FY2030 to determine equity valuation.
Why does Charles River Laboratories have a high proportion of goodwill and intangibles on its balance sheet?+
Charles River Laboratories' balance sheet features a significant proportion of goodwill and intangibles, making up about 60-65% of total assets. This is primarily due to the company's historical strategy of serial acquisitions, though recent impairments have led to a decrease in this percentage.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Healthcare Services Company Financial Models
Browse another company in the same sector.
Cardinal Health
Cardinal Health is a global healthcare services and products company that provides customised solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centres, and clinical laboratories.
Cencora
Cencora, formerly AmerisourceBergen, is one of the largest global pharmaceutical sourcing and distribution services companies.
Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic information services, offering clinical testing that ranges from routine blood work to complex genetic and oncology diagnostics.
DaVita
DaVita is a leading provider of kidney care services, primarily operating outpatient dialysis centres for patients with end-stage renal disease, while also managing value-based care arrangements and an expanding international dialysis network.
HCA Healthcare
HCA Healthcare is the largest for-profit operator of health care facilities in the United States, managing 190 hospitals and approximately 2,400 ambulatory sites of care.
Henry Schein
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, operating a global supply chain distributing over 300,000 products alongside software and e-services.
IQVIA
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, formed through the merger of Quintiles and IMS Health.
Labcorp
Laboratory Corporation of America Holdings (Labcorp) is a global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development services.
Explore more Healthcare financial model templates.
